Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04528199 · ClinicalTrials.gov registry record · Phase 1
[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04528199 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 8 participants.
The verdict
NCT04528199, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of \[18F\]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .
Interventions
- DRUG [18F]FLOR (FC303) Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04528199
The ClinicalTrials.gov registry entry for NCT04528199 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]FLOR (FC303) Injection is the first listed.
NCT04528199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04528199 about?
NCT04528199 is a clinical study titled "[18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer". The study is an open label, single-arm study designed to evaluate the safety and diagnostic performance of \[18F\]FLOR (FC303) PET/CT imaging to determine the presence or absence of metastatic prostate cancer. .
What is the current status of trial NCT04528199?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-02-01. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT04528199?
The interventions under investigation include: [18F]FLOR (FC303) Injection (DRUG).
Who is sponsoring clinical trial NCT04528199?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.